tbuckley/cabot-search huggingface dataset:
Relapses in metastatic germ-cell tumors and relationship to international guidelines compliance: A study from the Institut Gustave Roussy.
Authors: Constance Thibault, Yohann Loriot, Daniel Barrios Gonzales, Christophe Massard, Mario Di Palma, Alberto Bossi, Pierre Blanchard, Bernard J. Escudier, Jean Jacques Patard, Herve Baumert, Karim Fizazi
Journal: Journal of Clinical Oncology (2012)

323 Background: Germ-cell tumors (GCT) are rare but highly curable cancers even in patients with metastatic spread. We aimed at assessing whether relapse after upfront treatment could be explained by low compliance with international guidelines. Methods: All patients (pts) who were referred to Institut Gustave Roussy from 2000 to 2010 with progression or relapse after treatment for metastatic GCT were included. International guidelines available at the time of diagnosis were used as reference. A list of noncompliant criteria defined as disagreement with the recommendations with a potential impact on outcome was set up. Results: 78 pts were included. According to the IGCCCG classification, 18 pts (23.1%) had good, 25 pts (32%) had intermediary and 34 pts (43.6%) had poor prognosis. The first-line chemotherapy administered consisted of PEB regimen (70.5%) , PE regimen (15.4%) or other regimen (12.8%). Most patients were treated in cancer centers (52.5%, n=41), whereas 26.9% and 17.9% pts were treated in private or public general hospitals, respectively. Only 50% pts received treatment according to guidelines recommendations. This percentage was significantly higher in cancer centres than in public hospitals (75.6% versus 28.6%, p&lt; 0.001) or also when compared with private hospitals (75.6% versus 14,3%, p&lt;0.001). The most frequent noncompliance criteria were: time to surgery for residual mass (over 6 weeks after the latest chemotherapy cycle)(20.3%) and respected chemotherapy schedule (20.3%). Other noncompliance findings were: inadequate chemotherapy dose (15.6%), number of cycles (12.5%), decision regarding residual disease (12.5%), chemotherapy regimen (6.3%), follow up (4.6%), type of surgery (3.1%), staging(1.6%), IGCCCG classification (1.6%), or decision regarding chemotherapy after residual mass surgery (1.6%). Conclusions: This study suggests that the majority of relapse for metastatic GCT may be explained by a poor conformity to international guidelines and not only by aggressive tumor biology. These data represent a strong argument for treatment centralization in reference centers in patients with GCT.
Decitabine, low-dose cytarabine and aclarubicin combination with granulocyte colony-stimulating factor priming for the induction chemotherapy of older patients with myelodysplastic syndromes and acute myeloid leukemia
Authors: Sixuan Qian, Run Zhang, Yu Zhu, Hua Lu, Peng Liu, Hongxia Qiu, Hanxin Wu, Ming Hong, Jianyong Li
Journal: Blood (2012)
The Challenges of Generating Evidence to Support Precision Medicine
Authors: Mark J. Pletcher, Charles E. McCulloch
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Decitabine Activity in Chronic Myelomonocytic Leukemia Patients
Authors: Marcelo Iastrebner, Guy Garay, Graciela Klein, Alejandro Flores, Elsa Nucifora, Graciela Alfonso, Moro Diego, Ana Basquiera, Moira Lluesma Goalons, Diana Saracut, Miguel Gonzalez, Luis Quiroga, Luis Palmer, Fernando Santini
Journal: Blood (2008)
Alantolactone Induces Apoptosis in Imatinib-Sensitive and -Resistant CML Cells by Inhibiting NF-KappaB Signaling and Degrading Bcr/Abl Protein
Authors: Hua Yan, Wei Wei, Shan Zhao, Chuanxu Liu, Ying-Li Wu, Guo-Qiang Chen
Journal: Blood (2011)
Response to savolitinib (AZD6094/HMPL-504, a potent and selective MET inhibitor) in a papillary renal cell carcinoma patient harbouring a novel MET activating mutation
Authors: M.M. Frigault, D. Stetson, E. Maloney, J.F. Kramkowski, E. Barry, E.K. Lamberth, S. Signoretti, C. D'Cruz, B. Dougherty, J.C. Barrett, T.K. Choueiri
Journal: Annals of Oncology (2016)
Maximizing Psychotherapy Outcome beyond Evidence-Based Medicine
Authors: Michael J Lambert
Journal: Psychotherapy and Psychosomatics (2017)

Despite evidence that psychotherapy has a positive impact on psychological disorders, 30% of patients fail to respond during clinical trials, and as many as 65% of patients in routine care leave treatment without a measured benefit. In addition, therapists appear to overestimate positive outcomes in their patients relative to measured outcomes and are particularly poor at identifying patients at risk for a negative outcome. These problems suggest the need for measuring and monitoring patient treatment response over the course of treatment while applying standardized methods of identifying at-risk cases. Computer-assisted methods for measuring, monitoring, identifying potential deteriorators, and providing feedback to clinicians are described along with a model that explains why feedback is likely to be beneficial to patients. The results of 12 clinical trials are summarized and suggest that deterioration rates can be substantially reduced in at-risk cases (from baseline rates of 21% down to 13%) and that recovery rates are substantially increased in this subgroup of cases (from a baseline of 20% up to 35%) when therapists are provided this information. When problem-solving methods are added to feedback, deterioration in at-risk cases is further reduced to 6% while recovery/improvement rates rise to about 50%. It is suggested that the feedback methods become a standard of practice. Such a change in patterns of care can be achieved through minimal modification to routine practice but may require discussions with patients about their clinical progress.
Assessment of Multiple Myeloma IGHV Intraclonal Variation by Massively Parallel Pyrosequencing
Authors: Renee C. Tschumper, Yan W. Asmann, Asif Hossain, Paul M. Huddleston, Xiaosheng Wu, Angela Dispenzieri, Bruce W. Eckloff, Diane F. Jelinek
Journal: Blood (2011)
Extended genotyping of RAS/BRAF for improved selection of metastatic CRC patients to anti-EGFR therapy: Comparison of three platforms
Authors: D. Azuara, R. Garcia-Carbonero, P. García Alfonso, C. Santos-Vivas, V. Navarro, M. Varela, A. Carrato, E. Elez, M.T. Cano, F. Losa, C. Montagut, B. Massuti Sureda, J.L. Manzano, J. Vieitez, M. Valladares-Ayerbes, X. Sanjuan, G. Capellá, J. Tabernero, E. Aranda, R. Salazar
Journal: Annals of Oncology (2016)
ATIM-19. CATEGORIZING IMMUNE RESPONDERS WITH FUSION METRICS AND SIMULATION FOR ASSOCIATION TO SURVIVAL AND PROGRESSION FREE SURVIVAL WITH IMMUNE RESPONSE IN HLA-A2+ PATIENTS WITH GBM FROM A PHASE 2 TRIAL OF DENDRITIC CELL (DC) IMMUNOTHERAPY (ICT-107)
Authors: Radleigh Santos, Clemencia Pinilla, Steven J Swanson, Anthony Gringeri, John Yu
Journal: Neuro-Oncology (2016)

Detailed confirmatory testing and analysis verifies and strengthens the association between clinical outcomes and immune response of HLA-A2+ patients enrolled in a randomized phase 2 trial of ICT-107. 77 HLA-A2+ patients, randomized 2:1, received ICT-107 (autologous DCs incubated with 6 synthetic peptide CTL epitopes targeting GBM tumor/stem cell-associated antigens, including the four HLA-A2-restricted antigens HER-2, TRP-2, gp100, and IL-13Rα2) or matching control (un-incubated DC). Multimer testing was performed on a subset of these patients. The pioneering analysis heuristic of fusion metrics used in conjunction with Monte Carlo simulation was used to identify multimer immune responders. P-values between dependent variables and multiple overall survival (OS) or progression-free survival (PFS) metrics was performed using log-rank test and Fisher’s exact test. HLA-A2+ patients consistently continued to show evidence of immune response being associated with both OS and PFS. Multimer immune responders independently confirmed the ELISpot immune responder associations between assignment group (p=0.0308), and initial OS and PFS (p=0.0043 and 0.0352, respectively). Combining ELISpot and multimer responders strengthened or maintained associations with all OS and PFS metrics. Notable significant associations were determined when data was stratified by treatment group in both treatment and placebo subgroups, leading to speculation of the possible positive effects of DCs alone. This finding supports changing the placebo in the Phase III study from dendritic cells to PBMCs. The robust associations identified between OS and PFS with immunologic response, explored using both multimer and ELISpot analysis to determine immune response with fusion metrics in a Monte Carlo setting, provide support for the efficacy of ICT-107 to induce peptide-specific T cell responses in HLA-A2+ patients.
Three-Module Signaling Endo-Domain Artifical T-Cell Receptor Which Transmits CD28, OX40 and CD3-ζ Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells.
Authors: Martin A. Pule, Karin C. Straathof, Gianpietro Dotti, Helen E. Heslop, Cliona M. Rooney, Malcolm K. Brenner
Journal: Blood (2004)
In Vivo Blockade of Individual Notch Ligands and Receptors Provides a New Targeted Therapeutic Approach In Graft-Versus-Host Disease
Authors: Ivy T Tran, Ashley R Sandy, Alexis Carulli, Gloria T Shan, Vedran Radojcic, Ann Friedman, Amy Shelton, Linda C Samuelson, Minhong Yan, Christian W Siebel, Ivan Maillard
Journal: Blood (2011)
Efficacy and Safety of Re-Treatment with Bortezomib (Velcade©) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial
Authors: Maria Teresa Petrucci, Igor W. Blau, Paolo Corradini, Meletios A. Dimopoulos, Johannes Drach, Pilar Giraldo, Adriana Teixeira, Joan Blade
Journal: Blood (2008)
Differentiation Therapy for Poor Risk Myeloid Malignancies: Results of a Dose Finding Study of Bryostatin-1 (BRYO) + GM-CSF.
Authors: B. Douglas Smith, William H. Matsui, Douglas E. Gladstone, Judith E. Karp, Steven D. Gore, Carol Ann Huff, Milada Vala, Sharyn Baker, Ming Zhao, Steven Piantadosi, Richard J. Jones
Journal: Blood (2005)
An international multicentre hospital-based retrospective cohort study evaluating the prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients
Authors: M. Lambertini, A.C. Pinto, L. Ameye, L. Jongen, L. Del Mastro, F. Puglisi, M. Bonotto, F. Poggio, G. Floris, K. van Asten, H. Wildiers, P. Neven, E. de Azambuja, M. Paesmans, H.A. Azim
Journal: Annals of Oncology (2016)
Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial
Authors: P.A. Jänne, M. van den Heuvel, F. Barlesi, M. Cobo, J. Mazieres, L. Crinò, S. Orlov, F. Blackhall, J. Wolf, P. Garrido, A. Poltoratskiy, G. Mariani, D. Ghiorghiu, E. Kilgour, P. Smith, A. Kohlmann, D. Carlile, D. Lawrence, K. Bowen, J.F. Vansteenkiste
Journal: Annals of Oncology (2016)
Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization
Authors: Elena Magrini, Alessandra Villa, Francesca Angiolini, Andrea Doni, Giovanni Mazzarol, Noemi Rudini, Luigi Maddaluno, Mina Komuta, Baki Topal, Hans Prenen, Melitta Schachner, Stefano Confalonieri, Elisabetta Dejana, Fabrizio Bianchi, Massimiliano Mazzone, Ugo Cavallaro
Journal: Journal of Clinical Investigation (2014)

The article "Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma" is being retracted, with the agreement of the corresponding author.Several duplicated bands were recently identified in the immunoblot images in Figures 1 and3, and the authors are unable to retrieve the original source files that were used to generate these data.
TMIC-25. THE INFLAMMATORY LANDSCAPE OF GLIOBLASTOMAS IS HETEROGENEOUS AND MAY CORRELATE WITH PATIENT OUTCOME
Authors: Cymon Kersch, Cheryl Claunch-Rabe
Journal: Neuro-Oncology (2016)

Modulating interactions between the immune system and glioblastoma microenvironment is a promising area for therapeutics. However, little is known about the precise tumor-immune interface. Identifying heterogeneity in the inflammatory components within the tumor microenvironment may serve predictive and prognostic roles and help identify novel therapeutic targets. This study aims to define intra-tumoral heterogeneity and regional differences in the tumor-immune interface, and correlate this with patient outcomes. We mined public databases: the IVY Glioblastoma Atlas Project for RNA-sequencing and in situ hybridization data and Swedish IvyGAP Database, for correlating clinical data. Data is accessible at http://glioblastoma.alleninstitute.org. We queried expression of 250 genes (associated with tumor-immune interactions) in 7 histologic regions defined by Allen Brain Institute: leading edge, infiltrating tumor, cellular tumor, perinecrotic zones, pseudopalisading cells, hyperplastic blood vessels, and microvascular proliferation; 36 glioblastomas were included. Normalized gene expression levels were compared within and between regions to define spatial differences in tumor-immune interactions, and stratified by survival differences. Clusters of genes with similar expression patterns within regions were found applying graph theory. Regional patterns of inflammatory components were identified. Patients with survival greater vs less than median glioblastoma survival (14.6 months) had altered expression of pro and anti-inflammatory genes in different regions. In patients with longer vs shorter survival we observed increased IL10 and CD163 and decreased VTCN1, CD22, CD19, and CD6 in the infiltrative tumor, and elevated IL23A, CSF2 and IL6, with decreased INFA4, IL4, CD19, CD22, ICOS and ARG1 in perinecrotic zones. Patients with longer survival had increased expression of PDCD1 and CTLA4 in cellular tumor. Our preliminary analysis suggests that expression of immune-related genes in specific tumor regions may associate with patient outcomes. Further analysis of these patterns may provide insight into potential therapeutic targets and help predict sensitivity to immune modulatory therapies for glioblastoma.
Current status of biotherapies and chemotherapies for GEP-NETs
Authors: Masafumi Ikeda, Hideaki Takahashi, Yusuke Hashimoto, Izumi Ohno, Shuichi Mitsunaga, Kumiko Umemoto, Kazuo Watanabe, Chigusa Morizane, Takuji Okusaka
Journal: Annals of Oncology (2016)
SURG-12. LASER INTERSTITIAL THERMAL THERAPY (LITT) TO MANAGE PROGRESSED GLIOBLASTOMA DURING PREGNANCY
Authors: Na Tosha Gatson, Clement Pillainayagam, Ganesh Rao, T. Linda Chi, Sujit Prabhu, Shiao-Pei Weathers
Journal: Neuro-Oncology (2016)

Glioblastoma (GB) is the most lethal primary brain tumor in adults. Despite optimized multimodality treatment, median overall survival is 14-16 months. While these tumors inevitably progress, the rare concurrence with pregnancy has been demonstrated to increase aggressive tumor behavior through mechanisms that have not been clearly defined. Pregnancy further complicates the already limited available treatment options for recurrent GB (rGB) due to pregnancy-associated host immunosuppression, increased metabolic and vascular demands, and the need to avoid risks to the fetus. Here, we review the literature of reported neurosurgical interventions for rGB during pregnancy, and are first to report a clinical case using laser interstitial thermal therapy (LITT) to manage GB recurrence during pregnancy. This work discusses the unique challenges related to determining the neurosurgical approach, selecting medical treatment, arranging multidisciplinary clinical follow-up, and evaluating neuroimaging pre- and post-LITT procedure. Ultimately, this research offers potential indications and considerations for use of the LITT neurosurgical approach in pregnant patients with progressed disease.
Physiologic Inhibitors of Coagulation, Thrombophilic Acquired Factors and Venous Thromboembolism in Gastrointestinal Cancer Patients.
Authors: Gaia Schiavon, Odoardo M. Olimpieri, Barbara Giannetti, Maria C. Tirindelli, Annalisa La Cesa, Domenico Borzomati, Bruno Vincenzi, Roberto Coppola, Giuseppe Tonini, Giuseppe Avvisati
Journal: Blood (2004)
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i>- and <i>TET2</i>-Mutant Acute Myeloid Leukemia
Authors: Alan H. Shih, Cem Meydan, Kaitlyn Shank, Francine E. Garrett-Bakelman, Patrick S. Ward, Andrew M. Intlekofer, Abbas Nazir, Eytan M. Stein, Kristina Knapp, Jacob Glass, Jeremy Travins, Kim Straley, Camelia Gliser, Christopher E. Mason, Katharine Yen, Craig B. Thompson, Ari Melnick, Ross L. Levine
Journal: Cancer Discovery (2017)

Genomic studies in acute myeloid leukemias (AML) have identified mutations that drive altered DNA methylation, including
Expression of Cancer/Testis Antigens CT10 and SSX in Multiple Myeloma: Promising Targets for Antigen-Specific Immunotherapy.
Authors: Djordje Atanackovic, Julia Arfsten, Yanran Cao, Christine Wolschke, Katrin Bartels, Christiane Faltz, Dieter K. Hossfeld, Axel R. Zander, Carsten Bokemeyer, Nicolaus Kroeger
Journal: Blood (2005)
Histone Acetyltransferase Activity of MOF Is Required for <i>MLL-AF9</i> Leukemogenesis
Authors: Daria G. Valerio, Haiming Xu, Chun-Wei Chen, Takayuki Hoshii, Meghan E. Eisold, Christopher Delaney, Monica Cusan, Aniruddha J. Deshpande, Chun-Hao Huang, Amaia Lujambio, YuJun George Zheng, Johannes Zuber, Tej K. Pandita, Scott W. Lowe, Scott A. Armstrong
Journal: Cancer Research (2017)

Abstract Chromatin-based mechanisms offer therapeutic targets in acute myeloid leukemia (AML) that are of great current interest. In this study, we conducted an RNAi-based screen to identify druggable chromatin regulator–based targets in leukemias marked by oncogenic rearrangements of the MLL gene. In this manner, we discovered the H4K16 histone acetyltransferase (HAT) MOF to be important for leukemia cell growth. Conditional deletion of Mof in a mouse model of MLL-AF9–driven leukemogenesis reduced tumor burden and prolonged host survival. RNA sequencing showed an expected downregulation of genes within DNA damage repair pathways that are controlled by MOF, as correlated with a significant increase in yH2AX nuclear foci in Mof-deficient MLL-AF9 tumor cells. In parallel, Mof loss also impaired global H4K16 acetylation in the tumor cell genome. Rescue experiments with catalytically inactive mutants of MOF showed that its enzymatic activity was required to maintain cancer pathogenicity. In support of the role of MOF in sustaining H4K16 acetylation, a small-molecule inhibitor of the HAT component MYST blocked the growth of both murine and human MLL-AF9 leukemia cell lines. Furthermore, Mof inactivation suppressed leukemia development in an NUP98-HOXA9–driven AML model. Taken together, our results establish that the HAT activity of MOF is required to sustain MLL-AF9 leukemia and may be important for multiple AML subtypes. Blocking this activity is sufficient to stimulate DNA damage, offering a rationale to pursue MOF inhibitors as a targeted approach to treat MLL-rearranged leukemias. Cancer Res; 77(7); 1753–62. ©2017 AACR.
Nab-paclitaxel in substitution of oxaliplatin and irinotecan in folfirinox schedule as first-line therapy in patients with metastatic pancreatic cancer: results of phase I dose finding of NabucCO study by GOIRC
Authors: E. Giommoni, E. Maiello, G. Tortora, V. Vaccaro, E. Rondini, L. Toppo, G. Giordano, T.P. Latiano, L. Calvetti, L. Antonuzzo, C. Lamperini, L. Boni, F. Di Costanzo
Journal: Annals of Oncology (2016)
P01.12 VEGF-C contributes to autocrine VEGF Receptor 2 signaling and cellular maintenance in Glioblastoma
Authors: S. R. Michaelsen, M. K. Nedergaard, H. Broholm, J. Bartkova, M. Staberg, M. Aghi, S. Lucacova, L. Perryman, H. S. Poulsen, P. Hamerlik
Journal: Neuro-Oncology (2016)
FAS Mutations in Follicular Lymphoma Are Rare but Associated with Aggressive Clinical Behavior.
Authors: Nathalie A. Johnson, Ryan Morin, Tesa Severson, Andrew J. Mungall, Yongjun Zhao, Jacqueline E. Schein, Merrill Boyle, Bruce Woolcock, Richard Moore, Robert Holt, Douglas E. Horsman, Joseph M. Connors, Steven Jones, Martin Hirst, Marco A Marra, Randy D. Gascoyne
Journal: Blood (2009)
Synthetic Myocardial Extracellular Volume Fraction
Authors: Graham J. Fent, Pankaj Garg, James R.J. Foley, Peter P. Swoboda, Laura E. Dobson, Bara Erhayiem, Thomas A. Treibel, James C. Moon, John P. Greenwood, Sven Plein
Journal: JACC. Cardiovascular imaging (2017)
Impact of Hyponatremia in a Tertiary Cancer Center: a one-year-Survey at National Cancer Institute of Milan
Authors: F. Agustoni, G. Fucà, G. Corrao, C. Vernieri, S. Cavalieri, A. Raimondi, G. Peverelli, M. Prisciandaro, P. Indelicato, G. Lo Russo, D. Signorelli, C. Proto, M. Vitali, M. Imbimbo, N. Zilembo, M.C. Garassino, G. Procopio, F. de Braud, D. Morelli, M. Platania
Journal: Annals of Oncology (2016)